New Chinese-made drugs big hit overseas

Hutchmed CEO Su said the drug is already improving treatment prospects in the United States and China, and the company is looking forward to extending its impact to the European market. — China Daily

BEIJING: With more Chinese-developed innovative drugs entering both US and European markets, China’s pharmaceutical sector is showing escalating prowess in innovation and global market penetration, say industry experts.

“This (entering the European market) is a significant milestone. Fruquintinib is the first product approved in Europe completed by our research and development engine,” said Su Weiguo, CEO and chief scientific officer of Shanghai-based biopharmaceutical company Hutchmed.